VCYT Veracyte, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

VCYT [NASD]

Veracyte, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.62	Insider Own	1.10%	Shs Outstand	50.21M	Perf Week	4.45%
Market Cap	1.97B	Forward P/E	-	EPS next Y	-0.44	Insider Trans	-39.65%	Shs Float	50.12M	Perf Month	11.11%
Income	-30.90M	PEG	-	EPS next Q	-0.22	Inst Own	99.40%	Short Float	11.88%	Perf Quarter	30.61%
Sales	112.50M	P/S	17.47	EPS this Y	56.00%	Inst Trans	2.13%	Short Ratio	9.97	Perf Half Y	25.85%
Book/sh	4.50	P/B	7.51	EPS next Y	48.20%	ROA	-11.70%	Target Price	38.00	Perf Year	35.81%
Cash/sh	2.54	P/C	13.33	EPS next 5Y	-	ROE	-13.30%	52W Range	13.90 - 36.42	Perf YTD	21.02%
Dividend	-	P/FCF	-	EPS past 5Y	27.40%	ROI	-6.30%	52W High	-7.22%	Beta	0.86
Dividend %	-	Quick Ratio	12.60	Sales past 5Y	25.80%	Gross Margin	65.20%	52W Low	143.09%	ATR	1.71
Employees	354	Current Ratio	13.20	Sales Q/Q	-31.20%	Oper. Margin	-29.50%	RSI (14)	58.45	Volatility	3.74% 5.49%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-301.30%	Profit Margin	-27.50%	Rel Volume	0.60	Prev Close	34.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 30 AMC	Payout	-	Avg Volume	597.46K	Price	33.79
Recom	1.40	SMA20	5.04%	SMA50	16.96%	SMA200	28.21%	Volume	356,206	Change	-2.96%

Jul-31-19

Initiated

Lake Street

Buy

$35

Jul-02-19

Initiated

Needham

Buy

$33

Nov-29-18

Downgrade

Janney

Buy → Neutral

Oct-31-18

Upgrade

Janney

Neutral → Buy

Nov-07-17

Downgrade

Piper Jaffray

Overweight → Neutral

Nov-07-17

Downgrade

Janney

Buy → Neutral

Aug-31-17

Resumed

BTIG Research

Buy

$13

Nov-14-16

Resumed

Leerink Partners

Outperform

$12

Dec-18-15

Initiated

Cantor Fitzgerald

Buy

$13

Jun-11-15

Reiterated

Leerink Partners

Outperform

$11 → $13

Nov-26-13

Initiated

William Blair

Outperform

Aug-07-20 04:15PM	Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Aug-05-20 04:15PM	Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases Business Wire
03:26PM	Scaling Up Output of a Covid Vaccine Is Costly, Says Moderna Barrons.com
08:15AM	Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST Business Wire
Aug-04-20 07:27PM	Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock Business Wire -8.75%
Aug-03-20 04:10PM	Veracyte Announces Proposed Public Offering of Common Stock Business Wire
Aug-02-20 10:53AM	What Can We Learn About Veracyte's (NASDAQ:VCYT) CEO Compensation? Simply Wall St.
Jul-30-20 07:10PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates Zacks +10.04%
04:05PM	Veracyte Announces Second Quarter 2020 Financial Results Business Wire
08:15AM	Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians Ability to Diagnose IPF Without Surgery Business Wire
Jul-29-20 08:15AM	Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System Business Wire +6.19%
Jul-27-20 08:15AM	Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary Business Wire
Jul-23-20 12:33PM	Analysts Estimate Veracyte (VCYT) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-16-20 07:21PM	Veracyte Clears Technical Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
08:15AM	Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020 Business Wire
Jul-05-20 05:06PM	Is Veracyte Inc (VCYT) A Good Stock To Buy? Insider Monkey
Jun-29-20 02:06PM	Race for a COVID-19 vaccine has drug makers scaling up manufacturing before one is developed MarketWatch +6.03%
Jun-11-20 08:23AM	Moderna Will Start Testing Its Covid-19 Vaccine on 30,000 People in July Barrons.com -10.51%
07:30AM	Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifiers Ability to Improve IPF Diagnosis Business Wire
Jun-09-20 08:15AM	Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay Business Wire
Jun-04-20 05:00PM	Edited Transcript of VCYT earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-27-20 08:15AM	Veracyte to Present at the William Blair 40th Annual Growth Stock Conference Business Wire
May-22-20 06:22PM	Veracyte Earns Relative Strength Rating Upgrade To 80 Investor's Business Daily
07:29AM	Everything you need to know about the Oxford University vaccine and other efforts to beat coronavirus MarketWatch
May-21-20 08:15AM	Veracyte to Present at the Jefferies Virtual Healthcare Conference Business Wire
May-18-20 03:42PM	Coronavirus update: Moderna targets vaccine approval by year's end as reopenings continue Yahoo Finance
08:25AM	Lonza Group shares climb on positive Moderna vaccine trial MarketWatch
May-14-20 08:15AM	CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System Business Wire -6.46%
May-07-20 04:05PM	Veracyte to Present at the UBS Virtual Global Healthcare Conference Business Wire
09:31AM	Veracyte (VCYT) Q1 2020 Earnings Call Transcript Motley Fool
May-06-20 07:05PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Veracyte Announces First Quarter 2020 Financial Results Business Wire
03:00PM	Veracyte, Inc. to Host Earnings Call ACCESSWIRE
May-01-20 08:15AM	Veracyte Launches "More About You" Campaign to Educate Patients About Thyroid Cancer Diagnosis Business Wire
Apr-29-20 12:34PM	Veracyte (VCYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks +7.86%
Apr-23-20 01:07PM	CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis Business Wire
Apr-17-20 07:35AM	The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement Benzinga
Apr-16-20 04:30PM	Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic Business Wire
Apr-13-20 10:54AM	Why Veracyte (VCYT) Stock Might be a Great Pick Zacks
Apr-08-20 07:00PM	Stock Upgrades: Veracyte Shows Rising Relative Strength Investor's Business Daily
Apr-07-20 08:15AM	Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations Business Wire +6.32%
Apr-02-20 08:38AM	Veracyte, Inc. (NASDAQ:VCYT): When Will It Breakeven? Simply Wall St.
Apr-01-20 08:15AM	Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients Business Wire -16.58%
Mar-10-20 03:18AM	Edited Transcript of VCYT earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents +5.65%
Mar-02-20 11:00AM	Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy Business Wire +5.71%
Feb-26-20 10:28AM	Does Market Volatility Impact Veracyte, Inc.'s (NASDAQ:VCYT) Share Price? Simply Wall St.
Feb-25-20 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook Business Wire
Feb-13-20 08:15AM	Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-06-20 01:30PM	Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020 Business Wire
Jan-20-20 02:44PM	Should You Worry About Veracyte, Inc.'s (NASDAQ:VCYT) CEO Pay? Simply Wall St.
Jan-08-20 08:15AM	Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma Business Wire
Dec-13-19 09:06AM	Hedge Funds Might Be Selling Veracyte Inc (VCYT), But They Are Still Bullish Insider Monkey
Dec-04-19 11:56AM	Did Business Growth Power Veracyte's (NASDAQ:VCYT) Share Price Gain of 255%? Simply Wall St. +7.94%
07:06AM	The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 06:05PM	Peninsula diagnostics company's overseas plans could more than triple revenue American City Business Journals
05:09PM	$50M deal could expand NanoString Technologies diagnostic test into more markets American City Business Journals
05:00PM	Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally Business Wire
Nov-02-19 09:30AM	Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer Business Wire
Oct-31-19 04:30AM	8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 08:15AM	Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association Business Wire
Oct-27-19 02:00PM	Hedge Funds Have Never Been This Bullish On Veracyte Inc (VCYT) Insider Monkey
Oct-24-19 06:42AM	Edited Transcript of VCYT earnings conference call or presentation 22-Oct-19 9:00pm GMT Thomson Reuters StreetEvents -5.97%
Oct-22-19 04:15PM	Veracyte Announces Third Quarter 2019 Financial Results and Business Progress Business Wire
07:00AM	Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis Business Wire
Oct-21-19 04:15PM	Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive Business Wire +6.16%
09:57AM	Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis Business Wire
Oct-09-19 03:14PM	Are Veracyte, Inc. (NASDAQ:VCYT) Investors Paying Above The Intrinsic Value? Simply Wall St. +5.54%
Oct-08-19 04:30PM	Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019 Business Wire
Oct-07-19 08:00AM	Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019 Business Wire
Sep-11-19 11:04AM	Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas Business Wire
Sep-10-19 08:22AM	Loss-Making Veracyte, Inc. (NASDAQ:VCYT) Expected To Breakeven Simply Wall St.
Aug-28-19 04:15PM	Veracyte to Present at Upcoming Investor Conferences Business Wire
Aug-13-19 12:45PM	Is Veracyte (NASDAQ:VCYT) A Risky Investment? Simply Wall St. +6.69%
Aug-02-19 06:51PM	Edited Transcript of VCYT earnings conference call or presentation 30-Jul-19 9:00pm GMT Thomson Reuters StreetEvents -6.81%
Jul-31-19 01:24AM	Veracyte (VCYT) Q2 2019 Earnings Call Transcript Motley Fool
Jul-30-19 07:45PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:15PM	Veracyte Announces Second Quarter 2019 Financial Results Business Wire
Jul-23-19 10:32AM	Will Veracyte (VCYT) Report Negative Earnings Next Week? What You Should Know Zacks -7.47%
Jul-17-19 07:42AM	Is Veracyte, Inc.'s (NASDAQ:VCYT) CEO Pay Justified? Simply Wall St.
Jul-01-19 08:00AM	Veracyte Names Keith Kennedy Chief Operating Officer and Chief Financial Officer Business Wire
Jun-27-19 04:15PM	Veracyte to Release Second Quarter 2019 Financial Results on July 30, 2019 Business Wire
Jun-26-19 04:15PM	Veracyte Announces Next-Generation Percepta Genomic Sequencing Classifier Now Available to Physicians for Improved Lung Cancer Diagnosis Business Wire
Jun-24-19 08:30AM	Veracyte Named a San Francisco Bay Area Top Workplace For Sixth Consecutive Year Business Wire
Jun-21-19 09:35AM	Veracyte (VCYT) Hits Fresh High: Is There Still Room to Run? Zacks
Jun-20-19 03:29PM	Hedge Funds Have Never Been This Bullish On Veracyte Inc (VCYT) Insider Monkey
Jun-17-19 08:30AM	Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment Business Wire
Jun-14-19 02:59PM	7 Top-Rated Biotech Stocks to Invest In Today InvestorPlace
09:49AM	GE wants to unload the portfolio of its Menlo Park venture arm American City Business Journals
Jun-10-19 04:15PM	Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis Business Wire
Jun-07-19 09:26AM	Riskalyze hires Bay Area tech executive as CFO American City Business Journals
09:18AM	New Strong Buy Stocks for June 7th Zacks
Jun-01-19 02:15PM	Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis Business Wire
May-30-19 12:49PM	Before You Buy Veracyte, Inc. (NASDAQ:VCYT), Consider Its Volatility Simply Wall St.
May-29-19 04:20PM	Veracyte Announces Participation in Two Upcoming Investor Conferences Business Wire
May-23-19 08:00AM	Veracyte Announces New Data Demonstrating Afirma Xpression Atlass Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting Business Wire
May-20-19 08:00AM	Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis Business Wire
May-14-19 08:30AM	Veracyte Names Sangeeta Bhorade, M.D., Medical Director of Pulmonology Business Wire +5.27%
May-11-19 12:46PM	Hedge Funds Have Never Been This Bullish On Veracyte Inc (VCYT) Insider Monkey
May-09-19 04:20PM	Veracyte to Present at the UBS Global Healthcare Conference Business Wire

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Anderson Bonnie H	Chairman and CEO	Aug 10	Option Exercise	8.86	20,000	177,200	242,207	Aug 12 06:37 PM
JONES EVAN/ FA	Director	Aug 03	Sale	35.16	20,000	703,117	69,653	Aug 04 07:59 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 31	Option Exercise	20.21	20,000	404,200	100,487	Aug 04 08:05 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 31	Option Exercise	8.86	14,095	124,882	88,729	Aug 04 08:11 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 31	Sale	35.33	20,000	706,694	80,487	Aug 04 08:05 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 31	Sale	36.12	14,095	509,145	74,634	Aug 04 08:11 PM
JONES EVAN/ FA	Director	Jul 31	Sale	35.67	20,000	713,306	89,653	Aug 04 07:59 PM
Anderson Bonnie H	Chairman and CEO	Jul 30	Option Exercise	8.86	11,365	100,694	283,572	Jul 31 04:32 PM
Anderson Bonnie H	Chairman and CEO	Jul 30	Sale	32.24	11,365	366,399	272,207	Jul 31 04:32 PM
Anderson Bonnie H	Chairman and CEO	Jul 23	Option Exercise	8.86	3,280	29,061	275,487	Jul 27 05:04 PM
Anderson Bonnie H	Chairman and CEO	Jul 23	Sale	32.04	3,280	105,106	272,207	Jul 27 05:04 PM
Anderson Bonnie H	Chairman and CEO	Jul 22	Option Exercise	8.86	100	886	272,307	Jul 22 06:09 PM
Anderson Bonnie H	Chairman and CEO	Jul 22	Sale	32.00	100	3,200	272,207	Jul 22 06:09 PM
Anderson Bonnie H	Chairman and CEO	Jul 21	Option Exercise	8.86	3,447	30,540	275,654	Jul 22 06:09 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 21	Option Exercise	2.40	653	1,567	75,177	Jul 22 06:16 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 21	Sale	32.36	653	21,131	74,524	Jul 22 06:16 PM
Anderson Bonnie H	Chairman and CEO	Jul 21	Sale	32.09	3,447	110,614	272,207	Jul 22 06:09 PM
Anderson Bonnie H	Chairman and CEO	Jul 20	Option Exercise	8.42	20,349	171,287	292,556	Jul 22 06:09 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 20	Option Exercise	2.40	11,294	27,106	85,818	Jul 22 06:16 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 20	Sale	32.05	11,294	361,993	74,524	Jul 22 06:16 PM
Anderson Bonnie H	Chairman and CEO	Jul 20	Sale	32.04	20,349	651,911	272,207	Jul 22 06:09 PM
JONES EVAN/ FA	Director	Jul 15	Sale	30.12	10,000	301,192	109,653	Jul 16 05:15 PM
JONES EVAN/ FA	Director	Jul 14	Sale	28.34	20,000	566,847	119,653	Jul 16 05:15 PM
EPSTEIN ROBERT S	Director	Jul 13	Option Exercise	5.28	10,000	52,800	10,000	Jul 14 08:26 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 13	Option Exercise	13.05	16,738	218,373	97,225	Jul 14 08:29 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 13	Sale	29.66	16,738	496,478	80,487	Jul 14 08:29 PM
EPSTEIN ROBERT S	Director	Jul 13	Sale	29.73	10,000	297,252	0	Jul 14 08:26 PM
Kennedy Keith	COO / CFO	Jul 06	Option Exercise	7.67	47,658	365,351	200,309	Jul 07 05:47 PM
Kennedy Keith	COO / CFO	Jul 06	Sale	28.21	80,677	2,276,172	119,632	Jul 07 05:47 PM
Kennedy Keith	COO / CFO	Jul 02	Option Exercise	5.98	2,800	16,744	158,398	Jul 07 05:47 PM
Kennedy Keith	COO / CFO	Jul 02	Sale	28.02	5,747	161,040	152,651	Jul 07 05:47 PM
Anderson Bonnie H	Chairman and CEO	Jun 10	Option Exercise	4.00	20,000	80,000	292,207	Jun 11 07:06 PM
Anderson Bonnie H	Chairman and CEO	Jun 10	Sale	26.56	20,000	531,260	272,207	Jun 11 07:06 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jun 03	Option Exercise	7.54	10,239	77,251	91,273	Jun 04 04:16 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jun 03	Sale	26.22	10,786	282,809	80,487	Jun 04 04:16 PM
Cohen Fred E	Director	May 18	Sale	26.86	40,000	1,074,555	0	May 19 04:04 PM
Anderson Bonnie H	Chairman and CEO	May 11	Option Exercise	4.00	20,000	80,000	294,183	May 13 04:47 PM
Anderson Bonnie H	Chairman and CEO	May 11	Sale	26.67	20,000	533,334	274,183	May 13 04:47 PM
Anderson Bonnie H	Chairman and CEO	Mar 20	Option Exercise	2.68	16,000	42,880	272,313	Mar 23 05:01 PM
Anderson Bonnie H	Chairman and CEO	Mar 10	Option Exercise	4.00	20,000	80,000	276,313	Mar 11 05:05 PM
Anderson Bonnie H	Chairman and CEO	Mar 10	Sale	25.18	20,000	503,520	256,313	Mar 11 05:05 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Mar 03	Option Exercise	7.13	15,033	107,111	114,155	Mar 04 05:49 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Mar 03	Sale	25.39	32,881	834,798	81,274	Mar 04 05:49 PM
Kennedy Keith	COO / CFO	Jan 16	Option Exercise	7.47	7,052	52,678	116,755	Jan 21 04:23 PM
JONES EVAN/ FA	Director	Jan 16	Sale	30.11	14,049	422,975	139,653	Jan 21 04:25 PM
Kennedy Keith	COO / CFO	Jan 16	Sale	30.08	7,052	212,104	109,703	Jan 21 04:23 PM
JONES EVAN/ FA	Director	Jan 14	Sale	28.50	5,000	142,521	153,702	Jan 15 04:54 PM
Anderson Bonnie H	Chairman and CEO	Jan 10	Option Exercise	4.00	20,000	80,000	137,738	Jan 13 04:23 PM
Anderson Bonnie H	Chairman and CEO	Jan 10	Sale	28.86	20,000	577,276	117,738	Jan 13 04:23 PM
Kennedy Keith	COO / CFO	Dec 27	Option Exercise	7.47	400	2,988	110,103	Dec 31 04:09 PM
Kennedy Keith	COO / CFO	Dec 27	Sale	30.00	400	12,002	109,703	Dec 31 04:09 PM
JONES EVAN/ FA	Director	Dec 17	Sale	29.26	15,000	438,866	158,702	Dec 18 04:37 PM
Anderson Bonnie H	Chairman and CEO	Dec 10	Option Exercise	3.43	35,000	120,200	122,738	Dec 11 04:46 PM
Anderson Bonnie H	Chairman and CEO	Dec 10	Sale	28.96	20,000	579,248	102,738	Dec 11 04:46 PM
Hanna John Walter JR	Chief Commercial Officer	Dec 06	Option Exercise	9.05	9,838	89,034	75,113	Dec 09 04:17 PM
Kennedy Keith	COO / CFO	Dec 06	Option Exercise	7.47	13,851	103,467	123,554	Dec 09 04:12 PM
Hanna John Walter JR	Chief Commercial Officer	Dec 06	Sale	30.09	9,838	295,995	65,275	Dec 09 04:17 PM
JONES EVAN/ FA	Director	Dec 06	Sale	30.03	800	24,022	173,702	Dec 09 04:19 PM
Kennedy Keith	COO / CFO	Dec 06	Sale	30.04	13,851	416,146	109,703	Dec 09 04:12 PM
Kennedy Keith	COO / CFO	Dec 05	Option Exercise	6.90	19,300	133,208	129,003	Dec 09 04:12 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Dec 05	Option Exercise	14.34	32,803	470,395	79,665	Dec 09 04:15 PM
Hanna John Walter JR	Chief Commercial Officer	Dec 05	Option Exercise	9.05	8,100	73,305	73,375	Dec 09 04:17 PM
JONES EVAN/ FA	Director	Dec 05	Sale	30.00	5,151	154,535	174,502	Dec 09 04:19 PM
Hanna John Walter JR	Chief Commercial Officer	Dec 05	Sale	30.01	8,100	243,047	65,275	Dec 09 04:17 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Dec 05	Sale	29.39	32,803	964,142	46,862	Dec 09 04:15 PM
Kennedy Keith	COO / CFO	Dec 05	Sale	30.00	19,300	579,069	109,703	Dec 09 04:12 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Dec 03	Option Exercise	7.12	15,032	107,103	62,189	Dec 04 04:22 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Dec 03	Sale	26.47	15,327	405,663	46,862	Dec 04 04:22 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Nov 27	Option Exercise	14.34	3,697	53,015	51,146	Dec 02 04:13 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Nov 27	Sale	29.36	3,697	108,534	47,449	Dec 02 04:13 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 26	Option Exercise	8.99	15,497	139,346	80,989	Nov 27 04:30 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 26	Sale	28.55	15,497	442,480	65,492	Nov 27 04:30 PM
Kennedy Keith	COO / CFO	Nov 25	Option Exercise	5.98	18,757	112,167	128,800	Nov 27 04:28 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 25	Option Exercise	8.98	2,441	21,915	67,933	Nov 27 04:30 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 25	Sale	28.52	2,441	69,610	65,492	Nov 27 04:30 PM
Kennedy Keith	COO / CFO	Nov 25	Sale	28.01	18,757	525,475	110,043	Nov 27 04:28 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 18	Option Exercise	6.45	19,571	126,233	85,063	Nov 19 05:38 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 18	Sale	25.18	19,571	492,788	65,492	Nov 19 05:38 PM
Anderson Bonnie H	Chairman and CEO	Nov 15	Option Exercise	4.00	20,000	80,000	123,726	Nov 18 04:19 PM
Anderson Bonnie H	Chairman and CEO	Nov 15	Sale	25.06	20,000	501,124	103,726	Nov 18 04:19 PM
Kennedy Keith	COO / CFO	Oct 22	Option Exercise	5.98	1,243	7,433	111,286	Oct 24 06:39 PM
Hanna John Walter JR	Chief Commercial Officer	Oct 22	Option Exercise	6.45	16,091	103,787	81,583	Oct 24 06:42 PM
Hanna John Walter JR	Chief Commercial Officer	Oct 22	Sale	27.51	16,091	442,729	65,492	Oct 24 06:42 PM
Kennedy Keith	COO / CFO	Oct 22	Sale	28.00	1,243	34,804	110,043	Oct 24 06:39 PM
Anderson Bonnie H	Chairman and CEO	Oct 10	Option Exercise	3.09	7,300	22,546	111,726	Oct 11 04:25 PM
Anderson Bonnie H	Chairman and CEO	Oct 10	Sale	24.50	8,000	196,005	103,726	Oct 11 04:25 PM
Kennedy Keith	COO / CFO	Sep 18	Option Exercise	7.47	22,365	167,067	110,043	Sep 20 04:06 PM
Hanna John Walter JR	Chief Commercial Officer	Sep 16	Option Exercise	5.98	18,593	111,186	84,085	Sep 17 04:50 PM
Hanna John Walter JR	Chief Commercial Officer	Sep 16	Sale	25.66	18,593	477,089	65,492	Sep 17 04:50 PM
Anderson Bonnie H	Chairman and CEO	Sep 10	Sale	24.51	8,000	196,114	104,426	Sep 12 05:45 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Sep 04	Sale	25.20	296	7,458	47,449	Sep 05 05:23 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Sep 03	Option Exercise	7.13	15,031	107,100	63,068	Sep 05 05:23 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Sep 03	Sale	25.32	15,031	380,656	48,037	Sep 05 05:23 PM
JONES EVAN/ FA	Director	Aug 28	Sale	26.10	6,600	172,290	179,653	Aug 29 04:32 PM
JONES EVAN/ FA	Director	Aug 27	Sale	26.11	3,400	88,760	186,253	Aug 29 04:32 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience